Clinical Trial

Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR

Study acronym: AP
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This randomized trial will compare treatment strategies for proliferative diabetic retinopathy (PDR). Participants will receive either combination a of faricimab + PRP or vitrectomy + endolaser. The participants will be followed for 3 years. The study will evaluate long-term visual acuity as well as differences in number of injections, procedures, and complications during follow-up (after completion of randomization treatment), and cost.
Protocol Amendment History 1 change
notable Trial sites expanded: 20 -> 27 locations 2026-05-19
Trial Details
NCT Number NCT06790784
Lead Sponsor Jaeb Center for Health Research
Collaborators: National Eye Institute (NEI), Genentech, Inc.
Conditions Proliferative Diabetic Retinopathy (PDR)
Enrollment 426 participants
Start Date 2025-08-04
Primary Completion 2031-08 (estimated)
Study Completion 2031-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-16